MiR-29b is also found to be downregulated in cholangiocytes and cholangiocarcinoma cells as a function of NF-κB transcriptional activity since four NF-κB-binding sites are present in the region flanking the transcriptional start site at the promoter of MIR29B [132]. Here, NFKB1 is linked to cholangiocarcinoma.